

Special Issue

Feature Review Papers on Advanced Gastric Cancer

Message from the Guest Editors

Gastric cancer (GC) is the fifth most common and fourth most deadly cancer worldwide. The treatment of advanced gastric cancer has significantly developed over the last few years. As immune checkpoint inhibitors, anti-PD-1 antibodies have improved the prognosis of patients with metastatic GC. As a type of molecular target therapy, trastuzumab deruxtecan (T-Dxd), an antibody drug conjugate (ADC) for HER2, has shown significantly better outcomes compared with the physician's choice of chemotherapy as later-line treatment in HER2-positive GC patients. In addition, other molecular target drugs, such as claudin 18.2 and FGFR2b, in combination with chemotherapy have shown promising outcomes in HER2-negative GC patients. This Special Issue will highlight the recent advances in immunotherapy, molecular target therapy, and other potential treatments for advanced GC. Manuscripts that focus on comprehensive literature reviews of treatment, including peri-operative or systemic chemotherapy, for advanced GC patients are welcome. Other topics may also be of interest and will be considered.

Guest Editors

Prof. Dr. Yasuhide Yamada

Comprehensive Cancer Center, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

Dr. Naoki Takahashi

Department of Gastroenterology, Saitama Cancer Center, Saitama 362-0806, Japan

Deadline for manuscript submissions

closed (30 April 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/165110

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)